PTPN14

Across TCGA pan-cancer cohorts, PTPN14 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated PTPN14 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher PTPN14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTPN14 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

DLBC, LIHC, and UCEC are the cancer types where PTPN14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
LIHC	DFS	Median	II,III,IV	0.047	0.429	<.001	24	view →
UCEC	DFS	Median	All	0.845	0.613	.007	16	view →
PCPG	OS	Median	All	0.032	0.948	<.001	12	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	12	view →
ESCA	OS	Median	III,IV	0.108	0.574	<.001	12	view →
SKCM	DFS	Median	II,III,IV	0.490	0.202	.009	12	view →
KIRP	OS	Median	III,IV	0.268	0.808	.012	6	view →
SCLC	DFS	Median	All	0.164	0.566	.029	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	III,IV	0.036	0.673	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

PTPN14–DLBC (DFS)

Open the DLBC breakdown →